MOTS-c
$49.99
In stockMOTS-c is a 16-amino-acid mitochondrial-derived peptide studied in preclinical research involving cellular stress responses, metabolic homeostasis, skeletal-muscle signaling, and nuclear gene regulation.
| SKU | RC-ST-MOTSC-10MG |
|---|---|
| Manufacturer | Strandix Peptides |
| Form | Lyophilized Powder |
| Strength | 10 mg |
| Size | 3 mL Vial |
| Reported Result | See matching batch report |
| Stock | In stock |
| Documentation Status | Client-supplied report available |
MOTS-c is a mitochondrial-derived peptide encoded within a short open reading frame in the mitochondrial 12S rRNA region. The 16-amino-acid peptide was first described in research linking mitochondrial genetic information with metabolic signaling beyond the classical respiratory-chain proteins. Experimental work has evaluated MOTS-c in glucose and lipid metabolism, skeletal-muscle physiology, exercise responses, cellular stress adaptation, inflammatory pathways, and aging-related animal models. Research also suggests that MOTS-c can translocate to the nucleus under metabolic stress and influence nuclear gene expression. The evidence remains predominantly preclinical, with limited observational human biomarker research and no FDA-approved therapeutic indication.
Storage and handling: Follow the manufacturer label and matching batch documentation.
Third-party testing status.
| Batch / Lot | Reported Result | Tested | Partner | Status | Document |
|---|---|---|---|---|---|
| MS10/2026-04-06A | 99.029%; 99.012% | May 11, 2026 | Janoshik | Client-supplied report | View COA |
| MS10/2025-12-18-B | 99.722%; 99.766% | Dec 31, 2025 | Janoshik | Client-supplied report | View COA |
| MOTC-20260927 | 99.67%; net content 11.30 mg | Oct 15, 2026 | Freedom Diagnostics | Client-supplied report | View COA |
